MedKoo Cat#: 555760 | Name: DJ-V-159
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DJ-V-159 is a novel small molecule agonist of GPRC6A, dose-dependently stimulates cAMP production in GPRC6A expressing HEK-293 cells at 0.2 nM. DJ-V-159 demonstrated the greatest potency in stimulating insulin secretion in β-cells and lowering serum glucose in wild-type mice.

Chemical Structure

DJ-V-159
DJ-V-159
CAS#2253744-53-3

Theoretical Analysis

MedKoo Cat#: 555760

Name: DJ-V-159

CAS#: 2253744-53-3

Chemical Formula: C24H12F6N4O2

Exact Mass: 502.0864

Molecular Weight: 502.38

Elemental Analysis: C, 57.38; H, 2.41; F, 22.69; N, 11.15; O, 6.37

Price and Availability

Size Price Availability Quantity
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 1,950.00 2 Weeks
1g USD 2,950.00 2 Weeks
2g USD 5,250.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
DJ-V-159; DJ-V 159; DJ-V159; DJV-159; DJV 159; DJV159;
IUPAC/Chemical Name
N1,N3-Bis(4-cyano-3-(trifluoromethyl)phenyl)isophthalamide
InChi Key
VEVNLJLJLVESLL-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H12F6N4O2/c25-23(26,27)19-9-17(6-4-15(19)11-31)33-21(35)13-2-1-3-14(8-13)22(36)34-18-7-5-16(12-32)20(10-18)24(28,29)30/h1-10H,(H,33,35)(H,34,36)
SMILES Code
O=C(NC1=CC=C(C#N)C(C(F)(F)F)=C1)C2=CC=CC(C(NC3=CC=C(C#N)C(C(F)(F)F)=C3)=O)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
New insights into G protein coupled receptor regulation of glucose metabolism by β-cells, skeletal muscle and liver hepatocytes identify GPRC6A as a potential therapeutic target for treating type 2 diabetes mellitus (T2D). Activating GPRC6A with a small molecule drug represents a potential paradigm-shifting opportunity to make significant strides in regulating glucose homeostasis by simultaneously correcting multiple metabolic derangements that underlie T2D, including abnormalities in β-cell proliferation and insulin secretion and peripheral insulin resistance.
Product Data
Biological target:
DJ-V-159 is an agonist for G protein-coupled receptor family C group 6 member A (GPRC6A).
In vitro activity:
DJ-V-159 activates ERK in HEK-293 transfected with GPRC6A but not in non-transfected HEK-293 cells, with potency similar to L-Arg (Fig 5B). In addition, DJ-V-159 dose-dependently stimulated cAMP production in GPRC6A expressing HEK-293 cells, achieving a response a 0.2 nM concentrations in the media (Fig 5C). Reference: PLoS One. 2018 Apr 23;13(4):e0195980. https://pubmed.ncbi.nlm.nih.gov/29684031/
In vivo activity:
DJ-V-159 at the dose of 10 mg/kg reduced blood glucose levels in wild-type mice at 60 and 90 minutes after intraperitoneal administration of 10 mg/kg (Fig 6B), whereas the vehicle (95% PEG + 5% DMSO) had no effect on blood glucose (Fig 6C). DJ-V-159 reduced blood glucose levels in wild-type mice by 43.6% and 41.9% at 60 and 90 minutes, respectively, after intraperitoneal administration of 10 mg/kg (Fig 4B). Reference: PLoS One. 2018 Apr 23;13(4):e0195980. https://pubmed.ncbi.nlm.nih.gov/29684031/
Solvent mg/mL mM
Solubility
DMSO 15.5 30.85
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 502.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Pi M, Kapoor K, Ye R, Hwang DJ, Miller DD, Smith JC, Baudry J, Quarles LD. Computationally identified novel agonists for GPRC6A. PLoS One. 2018 Apr 23;13(4):e0195980. doi: 10.1371/journal.pone.0195980. PMID: 29684031; PMCID: PMC5912754.
In vitro protocol:
1. Pi M, Kapoor K, Ye R, Hwang DJ, Miller DD, Smith JC, Baudry J, Quarles LD. Computationally identified novel agonists for GPRC6A. PLoS One. 2018 Apr 23;13(4):e0195980. doi: 10.1371/journal.pone.0195980. PMID: 29684031; PMCID: PMC5912754.
In vivo protocol:
1. Pi M, Kapoor K, Ye R, Hwang DJ, Miller DD, Smith JC, Baudry J, Quarles LD. Computationally identified novel agonists for GPRC6A. PLoS One. 2018 Apr 23;13(4):e0195980. doi: 10.1371/journal.pone.0195980. PMID: 29684031; PMCID: PMC5912754.
Pi M, Kapoor K, Ye R, et al. Computationally identified novel agonists for GPRC6A. PLoS One. 2018;13(4):e0195980. Published 2018 Apr 23. doi:10.1371/journal.pone.0195980